Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial

Abstract

Background:

Severe pneumonia is one of the common acute diseases caused by pathogenic bacteria infection, especially by pathogenic bacteria, leading to sepsis with a high morbidity and mortality rate. However, the existing bacteria cultivation method cannot satisfy current clinical needs requiring rapid identification of bacteria strain for antibiotic selection. Therefore, developing a sensitive liquid biopsy system demonstrates the enormous value of detecting pathogenic bacterium species in pneumonia patients.

Methods:

In this study, we developed a tool named Species-Specific Bacterial Detector (SSBD, pronounce as "speed") for detecting selected bacterium. Newly designed diagnostic tools combining specific DNA-tag screened by our algorithm and CRISPR/Cas12a, which were first tested in the lab to confirm the accuracy, followed by validating its specificity and sensitivity via applying on bronchoalveolar lavage fluid (BALF) from pneumonia patients. In the validation I stage, we compared the SSBD results with traditional cultivation results. In the validation II stage, a randomized and controlled clinical trial was completed at the ICU of Nanjing Drum Tower Hospital to evaluate the benefit SSBD brought to the treatment.

Results:

In the validation stage I, 77 BALF samples were tested, and SSBD could identify designated organisms in 4 hours with almost 100% sensitivity and over 87% specific rate. In validation stage II, the SSBD results were obtained in 4 hours, leading to better APACHE II scores (p=0.0035, ANOVA test). Based on the results acquired by SSBD, cultivation results could deviate from the real pathogenic situation with polymicrobial infections. In addition, nosocomial infections were found widely in ICU, which should deserve more attention.

Funding:

National Natural Science Foundation of China. The National Key Scientific Instrument and Equipment Development Project. Project number: 81927808.

Clinical trial:

This study was registered at ClinicalTrilas.gov (NCT04178382).

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 3-5, Appendix figures 2-5, and Appendix tables 3-9.

Article and author information

Author details

  1. Yan Wang

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Xiaohui Liang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Yuqian Jiang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Danjiang Dong

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Cong Zhang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Tianqiang Song

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Ming Chen

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Yong You

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Han Liu

    Department of Critical Care Medicine, Nanjing Medical University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Min Ge

    Department of Cardiothoracic Surgery Intensive Care Unit, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  11. Haibin Dai

    Department of Neurosurgery Intensive Care Unit, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Fengchan Xi

    Research Institute of General Surgery, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  13. Wanqing Zhou

    Department of Laboratory Medicine, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  14. Jian-Qun Chen

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    Competing interests
    The authors declare that no competing interests exist.
  15. Qiang Wang

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    For correspondence
    wangq@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2907-9851
  16. Qihan Chen

    The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
    For correspondence
    chenqihan@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0062-8434
  17. Wenkui Yu

    Department of Critical Care Medicine, Nanjing University, Nanjing, China
    For correspondence
    yudrnj@nju.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4218-0321

Funding

National Natural Science Foundation of China (The National Key Scientific Instrument and Equipment Development Project,81927808)

  • Wenkui Yu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: We acquired the ethics approval (2019-197-01) from the ethics committee of Nanjing Drum Tower Hospital Affiliated to Nanjing University Medical School in July 2019, registered and posted the complete research protocol, informed consent, subject materials, case report form, researcher manual, the introduction of main researchers and other information in Chinese. Later on, this study was registered in English at ClinicalTrilas.gov (NCT04178382) in November 2019.

Copyright

© 2022, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,016
    views
  • 320
    downloads
  • 4
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yan Wang
  2. Xiaohui Liang
  3. Yuqian Jiang
  4. Danjiang Dong
  5. Cong Zhang
  6. Tianqiang Song
  7. Ming Chen
  8. Yong You
  9. Han Liu
  10. Min Ge
  11. Haibin Dai
  12. Fengchan Xi
  13. Wanqing Zhou
  14. Jian-Qun Chen
  15. Qiang Wang
  16. Qihan Chen
  17. Wenkui Yu
(2022)
Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial
eLife 11:e79014.
https://doi.org/10.7554/eLife.79014

Share this article

https://doi.org/10.7554/eLife.79014

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.